Bill Maughan

Adamas Pharmaceuticals Inc (NASDAQ: ADMS) shares were on a tear Friday following that the FDA has approved its GOCOVRI extended release capsules for dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without dopaminergic medications. At the time of...